Quick Answer
ProMIS Neurosciences Inc. reported Cash and Equivalents of $6.12 million for fiscal year 2025.
ProMIS Neurosciences Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $6.12M | -54.0% |
| 2024 | $13.29M | +5.5% |
| 2023 | $12.60M | +114.4% |
| 2022 | $5.88M | -65.3% |
| 2021 | $16.94M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $15.40M | -28.5% | +241.4% |
| June 30, 2025 | $4.51M | +354.4% | -46.1% |
| March 31, 2025 | $8.36M | +235.0% | -37.1% |
| December 31, 2024 | $13.29M | +5.5% | -38.3% |
| September 30, 2024 | $21.54M | +27.7% | +2070.0% |
| June 30, 2024 | $992.5K | -18.8% | -60.3% |
| March 31, 2024 | $2.50M | -25.1% | -80.2% |
| December 31, 2023 | $12.60M | +114.4% | -25.3% |
- ProMIS Neurosciences Inc. showed a decrease of -54.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2025 period, ProMIS Neurosciences Inc.’s cash and equivalents has declined by 63.9% (from $16.94 million to $6.12 million).
- The most recent figure is from ProMIS Neurosciences Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: